83 FR 22498 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 83, Issue 94 (May 15, 2018)
National Institutes of Health
Federal Register Volume 83, Issue 94 (May 15, 2018)
| Page Range | 22498-22498 | |
| FR Document | 2018-10316 |
[Federal Register Volume 83, Number 94 (Tuesday, May 15, 2018)] [Notices] [Page 22498] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-10316] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of Microbiology, Infectious Diseases and AIDS Initial Review Group Microbiology and Infectious Diseases Research Committee. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Microbiology, Infectious Diseases and AIDS Initial Review Group Microbiology and Infectious Diseases Research Committee. Date: June 7-8, 2018. Time: 9:30 a.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Frank S. De Silva, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3E72A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892934, (240) 669-5023, [email protected]. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: May 10, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018-10316 Filed 5-14-18; 8:45 am] BILLING CODE 4140-01-P
![22498 Federal Register / Vol. 83, No. 94 / Tuesday, May 15, 2018 / Notices
ORI found that Respondent engaged (2) that for one (1) year, any Name of Committee: Microbiology,
in research misconduct by knowingly institution employing him shall submit, Infectious Diseases and AIDS Initial Review
and intentionally falsifying data in conjunction with each application for Group Microbiology and Infectious Diseases
PHS funds, or report, manuscript, or Research Committee.
reported in Development 141(12):2414–
Date: June 7–8, 2018.
28, 2014 Jun (hereafter referred to as abstract involving PHS-supported Time: 9:30 a.m. to 4:30 p.m.
‘‘Development 2014’’). research in which Respondent is Agenda: To review and evaluate grant
In addition to making an admission, involved, a certification to ORI that the applications.
Respondent cooperated fully with data provided by Respondent are based Place: National Institutes of Health, 5601
ISMMS and ORI and has expressed on actual experiments or are otherwise Fishers Lane, Rockville, MD 20892
remorse for his actions. legitimately derived and that the data, (Telephone Conference Call).
Specifically, ORI found that procedures, and methodology are Contact Person: Frank S. De Silva, Ph.D.,
Respondent: accurately reported in the application, Scientific Review Officer, Scientific Review
• used the p-GSK3a/b double bands report, manuscript, or abstract;
Program, Division of Extramural Activities,
in Figure S3B of Development 2014, Room #3E72A, National Institutes of Health/
(3) if no supervisory plan is provided NIAID, 5601 Fishers Lane, MSC 9834,
removed the lower set of bands, to ORI, to provide certification to ORI at Bethesda, MD 20892934, (240) 669–5023,
reordered the remaining bands and used the conclusion of the supervision period fdesilva@niaid.nih.gov.
those bands to represent the actin that he has not engaged in, applied for, (Catalogue of Federal Domestic Assistance
control in an experiment comparing the or had his name included on any Program Nos. 93.855, Allergy, Immunology,
impact of Tgfb1 and ActB individually application, proposal, or other request and Transplantation Research; 93.856,
and in combination in primary for PHS funds without prior notification Microbiology and Infectious Diseases
oligodendrocyte progenitors (OLPs) and to ORI; Research, National Institutes of Health, HHS)
the oligodendrocyte-derived Oli-Neu (4) to exclude himself voluntarily Dated: May 10, 2018.
cell line. from serving in any advisory capacity to Natasha M. Copeland,
• used the densitometry readings PHS including, but not limited to,
from the falsified actin bands in Figure Program Analyst, Office of Federal Advisory
service on any PHS advisory committee, Committee Policy.
S3B of Development 2014 to compare board, and/or peer review committee, or [FR Doc. 2018–10316 Filed 5–14–18; 8:45 am]
the density of A+T, Tgfb1, ActB, and as a consultant for a period of one (1)
Veh relative to the false actin signal in BILLING CODE 4140–01–P
year; and
Figure S3C–J, creating eight false (5) to follow up with the journal
graphs. editor regarding his previous request to
• falsified the bands representing DEPARTMENT OF HEALTH AND
correct the following paper to ensure HUMAN SERVICES
Myelin basic protein (Mbp) in Figure 3C that the corrections are made:
of Development 2014 by cutting and • Development 141(12):2414–28, National Institutes of Health
pasting the bands onto a blank 2014 Jun.
background and used those false bands National Institute of Biomedical
to create a graph showing the density of Wanda K. Jones,
Imaging and Bioengineering; Notice of
Mbp in the presence and absence of Interim Director, Office of Research Integrity.
Closed Meeting
ActB, Tgfb1, and Bmp4. [FR Doc. 2018–10310 Filed 5–14–18; 8:45 am]
As a result of this admission, BILLING CODE 4150–31–P Pursuant to section 10(d) of the
Respondent has notified Development Federal Advisory Committee Act, as
that corrections to figures in the paper, amended, notice is hereby given of the
but not to the text, including the DEPARTMENT OF HEALTH AND meeting of the National Institute of
conclusions in Development 2014 are HUMAN SERVICES Biomedical Imaging and Bioengineering
required. Special Emphasis Panel.
Dr. John entered into a Voluntary National Institutes of Health The meeting will be closed to the
Settlement Agreement and voluntarily public in accordance with the
National Institute of Allergy and provisions set forth in sections
agreed, beginning on April 26, 2018:
(1) To have his research supervised Infectious Diseases; Notice of Closed 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
for a period of one (1) year; Respondent Meeting as amended. The grant applications and
agreed that prior to submission of an Pursuant to section 10(d) of the the discussions could disclose
application for U.S. Public Health Federal Advisory Committee Act, as confidential trade secrets or commercial
Service (PHS) support for a research amended, notice is hereby given of a property such as patentable material,
project on which the Respondent’s meeting of Microbiology, Infectious and personal information concerning
participation is proposed and prior to Diseases and AIDS Initial Review Group individuals associated with the grant
Respondent’s participation in any Microbiology and Infectious Diseases applications, the disclosure of which
capacity on PHS-supported research, Research Committee. would constitute a clearly unwarranted
Respondent shall ensure that a plan for The meeting will be closed to the invasion of personal privacy.
supervision of Respondent’s duties is public in accordance with the Name of Committee: National Institute of
submitted to ORI for approval; the provisions set forth in sections Biomedical Imaging and Bioengineering
supervision plan must be designed to 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Special Emphasis Panel; P41 BTRC Review
ensure the scientific integrity of as amended. The grant applications and (2018/10).
Respondent’s research contribution; the discussions could disclose Date: July 5–7, 2018.
daltland on DSKBBV9HB2PROD with NOTICES
Respondent agreed that he shall not confidential trade secrets or commercial Time: 6:00 p.m. to 1:00 p.m.
participate in any PHS-supported property such as patentable material, Agenda: To review and evaluate grant
applications and/or proposals.
research until such a supervision plan is and personal information concerning Place: Courtyard by Marriott New York
submitted to and approved by ORI; individuals associated with the grant Manhattan/Upper ES, 410 East 92nd Street,
Respondent agreed to maintain applications, the disclosure of which New York, NY 10128.
responsibility for compliance with the would constitute a clearly unwarranted Contact Person: Manana Sukhareva, Ph.D.,
agreed upon supervision plan; invasion of personal privacy. Scientific Review Officer, National Institute
VerDate Sep<11>2014 20:27 May 14, 2018 Jkt 244001 PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 E:\FR\FM\15MYN1.SGM 15MYN1](https://thefederalregister.org/doc/83_FR_22592/page/1.svg)
Document Created: 2018-05-15 00:33:26
Document Modified: 2018-05-15 00:33:26
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | June 7-8, 2018. | |
| FR Citation | 83 FR 22498 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR